Retatrutide is an investigational, once-weekly injectable medication currently in clinical development for the treatment of obesity, type 2 diabetes, and related metabolic conditions. Retatrutide is a novel triple hormone receptor agonist that targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously—making it one of the most comprehensive metabolic agents in development. This product is intended for laboratory research use only. It is not approved for human consumption or medical use. All research must be conducted by qualified professionals in controlled settings.